Predictive Technology Group, Inc. (Pred) Retains Donohoe Advisory Associates Llc, To Assist In Preparing To Seek A Listing On A National Securities Exchange

Salt Lake City, UT- February 27, 2018- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that it has engaged Donohoe Advisory Associates, LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a national securities exchange.

Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of companies in a wide range of listing proceedings and engagements at both Nasdaq and the NYSE. Each professional member of Donohoe Advisory’s team previously worked for either The Nasdaq Stock Market (“Nasdaq”) or the New York Stock Exchange (the “NYSE”).  Prior to forming Donohoe Advisory, Dave Donohoe spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.

Bradley Robinson, CEO, Predictive Technology Group, Inc. states, “At this juncture in PRED’s corporate growth, PRED believes it is well positioned to pursue a listing on a recognized exchange.  Hiring Donohoe Advisory will help to further this effort.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED’s subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively,, and

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.